Receptor Life Sciences raises $29M Series A to advance inhaled dry‑powder cannabinoid medicines and start FDA IND process
Receptor Life Sciences, led by CEO Gregory Wesner, raised $29 million in its first Series A to advance an inhaler delivering dry powdered cannabinoid medicines and begin the FDA investigational new drug process while formalizing collaborations in Canada and Europe.